AptaTargets is a clinical-stage biopharmaceutical company developing therapeutic aptamers to target inflammation in acute medical conditions such as ischemic stroke and myocardial infarction. Their lead candidate, ApTOLL, uniquely inhibits TLR4 activation to provide neuroprotection during the acute phase of stroke, addressing significant damage caused by inflammatory responses.
Funding
Funding not disclosed
EAFounders
Product
Problem
Ischemic stroke and myocardial infarction cause significant damage due to inflammation during the acute phase. Current treatments do not adequately address the inflammatory response that exacerbates tissue damage following these events.
Solution
AptaTargets is developing ApTOLL, a therapeutic aptamer that targets TLR4 activation to modulate inflammation in acute medical conditions. ApTOLL is designed to provide neuroprotection during the acute phase of ischemic stroke by inhibiting the inflammatory cascade triggered by TLR4. Preclinical models of ischemic stroke have demonstrated that ApTOLL reduces brain damage by up to 65% within a 12-hour therapeutic window. The company is advancing ApTOLL through clinical trials, with the goal of demonstrating a clinical proof-of-concept in patients. AptaTargets is also exploring the potential of ApTOLL in other indications where TLR4 plays a key role, including intracerebral hemorrhage, myocardial infarction, and multiple sclerosis.
Target Audience
The primary target audience includes patients at risk of or experiencing acute ischemic stroke and myocardial infarction, as well as medical professionals in neurology and cardiology.
Features
- First-in-class aptamer (single-stranded DNA molecule) targeting TLR4
- Selectively antagonizes TLR4 to modulate the immune response
- Demonstrated neuroprotective effect in experimental models of ischemic stroke
- Reduces brain damage by up to 65% in preclinical studies
- Excellent safety profile confirmed by preclinical and early clinical data
- Potential application in intracerebral hemorrhage, myocardial infarction, and multiple sclerosis